Monitoring Parameters When Switching from 17-Hour to 19-Hour Weekly Hemodialysis
When increasing hemodialysis time from 17 to 19 hours per week, you must monitor vascular access complications, blood pressure/volume status, residual kidney function, and metabolic parameters including phosphate, potassium, and hemoglobin.
Critical Monitoring Framework
1. Vascular Access Surveillance (Highest Priority)
- Increased access procedures are the most significant risk when extending dialysis hours 1
- Monitor for:
- Signs of access thrombosis or stenosis
- Bleeding complications
- Infection at access site
- Flow rates and pressures during each session
- Examine access before each treatment and document any changes
2. Blood Pressure and Volume Management
Monitor both intradialytic hemodynamic stability and interdialytic blood pressure control:
- Intradialytic hypotension risk increases with longer sessions 1
- Measure BP pre-, intra-, and post-dialysis at each session
- Home BP monitoring is superior to peridialytic measurements for assessing true hypertension control 2
- If available, use 44-hour ambulatory BP monitoring (gold standard)
- Alternative: home BP twice daily for 4 days after midweek treatment
- Track ultrafiltration rates—aim to keep below thresholds that cause hemodynamic instability 1
- Reduction in ultrafiltration rate with longer sessions improves left ventricular parameters 3
- Assess for volume overload: interdialytic weight gains, edema, dry weight achievement 1
3. Residual Kidney Function (RKF)
- Longer frequent hemodialysis accelerates decline in RKF 1
- Measure urine output and urine urea clearance (Kru) at baseline and periodically (every 1-3 months initially) 1
- If RKF declines significantly, reassess dialysis prescription
4. Dialysis Adequacy
- Target standard Kt/V of 2.3 volumes per week (minimum 2.1) for non-thrice-weekly schedules 1
- Calculate using method that includes ultrafiltration and residual kidney function contributions
- Measure within first month after schedule change, then quarterly
5. Metabolic Parameters
Phosphate:
- Expect significant reduction with longer hours 4, 5
- Monitor monthly initially—may need to reduce or discontinue phosphate binders 4
- Some patients may require phosphate supplementation in dialysate 4
Potassium:
- Typically decreases with extended hours 4, 5
- Monitor pre-dialysis levels monthly
- May need to increase dialysate potassium concentration 4
Hemoglobin and Anemia Management:
- Extended hours often improve hemoglobin levels 5
- Monitor monthly—may reduce erythropoietin-stimulating agent doses 4, 5
- Track iron parameters (transferrin saturation, ferritin) 5
Calcium-Phosphate-PTH Axis:
- Monitor calcium, phosphate, intact PTH quarterly 4, 5
- Note: PTH may paradoxically increase 3-fold in patients with intact parathyroid glands despite stable alkaline phosphatase 5
6. Nutritional Status
- Longer dialysis hours can improve nutritional parameters 5
- Monitor:
- Body weight and dry weight trends
- Serum albumin quarterly
- Normalized protein catabolic rate (nPCR)
- Consider bioelectrical impedance analysis if available
7. Medication Adjustments
Anticipate and monitor for needed reductions in:
- Antihypertensive medications (may reduce by 2-3 agents) 4, 5
- Phosphate binders (60% of patients may discontinue) 4
- Erythropoietin-stimulating agents 4, 5
Monitoring Timeline
First Month:
- Weekly: BP (home if possible), weight gains, access examination
- At 2-4 weeks: Kt/V, phosphate, potassium, hemoglobin
- At 4 weeks: RKF assessment, full metabolic panel
Months 2-6:
- Each session: BP, access examination, intradialytic symptoms
- Monthly: Phosphate, potassium, hemoglobin
- Quarterly: Full CKD-MBD panel, albumin, Kt/V
After 6 Months:
- Standard maintenance monitoring per KDOQI guidelines
- Continue vigilance for access complications
Common Pitfalls to Avoid
- Failing to reduce medications proactively—patients may develop hypotension or hypophosphatemia if binders and antihypertensives aren't adjusted
- Relying solely on pre/post-dialysis BP—these are poor predictors of true BP control and cardiovascular risk 2
- Not monitoring RKF—this is a modifiable risk factor that worsens with extended hours 1
- Missing the paradoxical PTH rise—this occurs despite improved phosphate control and doesn't necessarily indicate worsening bone disease 5